Post hoc analysis finds NCX 4251 may be effective in some patients with dry eye
Click Here to Manage Email Alerts
NCX 4251 may be effective at reducing dry eye disease symptoms in a specific subgroup of patients, according to a press release from Nicox.
NCX 4251(fluticasone propionate ophthalmic suspension 0.1%) failed to meet primary or secondary efficacy endpoints in the phase 2b Mississippi clinical trial, but it may have a path forward following a post hoc analysis of the study results.
In a subgroup of patients with baseline scores of 2 or greater on a scale of 0 to 4 for inferior cornea fluorescein staining, the post hoc analysis showed a statistically significant change from baseline in eye dryness scores as assessed on a visual analog scale with once-daily NCX 4251 compared with placebo, the release said. The change was significant at day 8 (P = .0085), day 11 (P = .0020) and day 15 (P < .0016).
“The positive impact of NCX 4251 on the multitude of symptoms associated with dry eye disease in a substantial subgroup of blepharitis patients in the trial provides a compelling rationale to explore a targeted approach to the future development of the program with the FDA,” Michele Garufi, chairman and CEO of Nicox, said in the release.
Nicox plans to discuss with the FDA a potential alternative development path for the drug in 2022.
Read more about
Click Here to Manage Email Alerts